Page last updated: 2024-09-05

dabigatran and ER-Negative PR-Negative HER2-Negative Breast Cancer

dabigatran has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Buijs, JT; Crooijmans, JJ; Kroone, C; Laghmani, EH; Le Dévédec, SE; Tieken, C; van den Akker, RFP; van der Molen, KM; van der Pluijm, G; Versteeg, HH; Vletter, EM	1

Other Studies

1 other study(ies) available for dabigatran and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice. Journal of thrombosis and haemostasis : JTH, 2019, Volume: 17, Issue:6 Topics: Animals; Anticoagulants; Antithrombins; Breast Neoplasms; Cell Line, Tumor; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Rivaroxaban; Triple Negative Breast Neoplasms; Venous Thromboembolism; Xenograft Model Antitumor Assays	2019

Article

Year

The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.

Journal of thrombosis and haemostasis : JTH, 2019, Volume: 17, Issue:6

Topics: Animals; Anticoagulants; Antithrombins; Breast Neoplasms; Cell Line, Tumor; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Rivaroxaban; Triple Negative Breast Neoplasms; Venous Thromboembolism; Xenograft Model Antitumor Assays

2019